Anavex Life Sciences Corp (AVXL)

[sokol]

Nidan:

Yes, data from all AD studies I believe is relevant whether it be evidence from past Anavex studies or evidence from other studies that may be used for comparison.

This analysis announced this morning where AD patients in the Phase 2a ANAVEX®2-73 (blarcamesine) cohort and AD patients from the ADNI control cohort were compared is certainly relevant and another meaningful piece of evidence. If this and all other evidence compares favorably with what will be revealed once data is analyzed and available from the ongoing Anavex trials, that will confirm the benefit of AVXL 2-73, buttress this study announced today, and will be unsurpassed any AD drug thus far.

One question that I would like to know is whether the patients selected from the ADNI data base were treated with any approved AD drug. If those patients were treated with any AD approved drugs, this could make the comparison to AVXL 2-73 even more significant.